Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma

被引：4
|
作者：
Shimabukuro-Vornhagen, A. [1 ]
Josting, A. [1 ]
Huebel, K. [1 ]
Scheid, C. [1 ]
Dietlein, M. [1 ]
Engert, A. [1 ]
Schnell, R. [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8615
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience
    Ciochetto, Chiara
    Botto, Barbara
    Passera, Roberto
    Bello, Marilena
    Benevolo, Giulia
    Boccomini, Carola
    Castellino, Alessia
    Chiappella, Annalisa
    Freilone, Roberto
    Nicolosi, Maura
    Orsucci, Lorella
    Pecoraro, Clara
    Pregno, Patrizia
    Bisi, Gianni
    Vitolo, Umberto
    ANNALS OF HEMATOLOGY, 2018, 97 (09) : 1619 - 1626
  • [22] Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience
    Chiara Ciochetto
    Barbara Botto
    Roberto Passera
    Marilena Bellò
    Giulia Benevolo
    Carola Boccomini
    Alessia Castellino
    Annalisa Chiappella
    Roberto Freilone
    Maura Nicolosi
    Lorella Orsucci
    Clara Pecoraro
    Patrizia Pregno
    Gianni Bisi
    Umberto Vitolo
    Annals of Hematology, 2018, 97 : 1619 - 1626
  • [23] INTERIM ANALYSIS OF POST MARKETING SURVEILLANCE OF YTTRIUM-90 IBRITUMOMAB TIUXETAN IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA
    Hatake, K.
    Kanzaki, R.
    Yabuuchi, Y.
    Kataoka, O.
    Nagai, S.
    Asaeda, Y.
    HAEMATOLOGICA, 2016, 101 : 273 - 273
  • [24] Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen
    Mei, Matthew
    Wondergem, Marielle J.
    Palmer, Joycelynne M.
    Shimoni, Avichai
    Hasenkamp, Justin
    Tsai, Ni-Chun
    Simpson, Jennifer
    Nademanee, Auayporn
    Raubitschek, Andrew
    Forman, Stephen J.
    Krishnan, Amrita Y.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) : 2072 - 2075
  • [25] Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Wiseman, GA
    Witzig, TE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S221 - S221
  • [26] Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial
    Briones, Javier
    Novelli, Silvana
    Garcia-Marco, Jose A.
    Tomas, Jose F.
    Bernal, Teresa
    Grande, Carlos
    Canales, Miguel A.
    Torres, Antonio
    Moraleda, Jose M.
    Panizo, Carlos
    Jarque, Isidro
    Palmero, Francisca
    Hernandez, Miguel
    Gonzalez-Barca, Eva
    Lopez, Dulce
    Caballero, Dolores
    HAEMATOLOGICA, 2014, 99 (03) : 505 - 510
  • [27] Radioimmunotherapy with 90Y Ibritumomab Tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Olivas, C.
    Bello, P.
    Vercher, J. L.
    Loaiza, J. L.
    Marti, J. F.
    Hervas, I.
    Rivas, A.
    Ruiz, C.
    Perez-Velasco, R.
    Mateo, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
  • [28] Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
    Gisselbrecht, C.
    Bethge, W.
    Duarte, R. F.
    Gianni, A. M.
    Glass, B.
    Haioun, C.
    Martinelli, G.
    Nagler, A.
    Pettengell, R.
    Sureda, A.
    Tilly, H.
    Wilson, K.
    BONE MARROW TRANSPLANTATION, 2007, 40 (11) : 1007 - 1017
  • [29] Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
    C Gisselbrecht
    W Bethge
    R F Duarte
    A M Gianni
    B Glass
    C Haioun
    G Martinelli
    A Nagler
    R Pettengell
    A Sureda
    H Tilly
    K Wilson
    Bone Marrow Transplantation, 2007, 40 : 1007 - 1017
  • [30] Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL).
    Khouri, Issa F.
    Saliba, Rima M.
    Hosing, Chitra
    Valverde, Rosamar
    Erwin, William D.
    Fayad, Luis
    Maadani, Farzaneh
    Korbling, Martin J.
    Okoroji, Grace-Julia
    Stachowiak, Anne M.
    Samuels, Barry I.
    Anderlini, Paolo
    Couriel, Daniel R.
    de Lima, Marcos
    Giralt, Sergio
    Popat, Uday
    Kebriaei, Partow
    Ueno, Naoto T.
    Qazilbash, Muzaffar H.
    McLaughlin, Peter W.
    Hagemeister, Fredrick B.
    Younes, Anas
    Podoloff, Donald A.
    Champlin, Richard E.
    BLOOD, 2006, 108 (11) : 98A - 98A
12345